Vlasoff Dmitry M, Baschinsky Dmitry Y, De Young Barry R, Morrison Carl D, Nuovo Gerard J, Frankel Wendy L
Department of Pathology, Ohio State University, Columbus, Ohio 43210-1228, USA.
Appl Immunohistochem Mol Morphol. 2002 Sep;10(3):237-41. doi: 10.1097/00129039-200209000-00009.
The human c-erb B2 proto-oncogene (Her2/ ) encodes a 185-kD transmembrane putative growth factor receptor of the tyrosine kinase family. Overexpression or amplification of this oncoprotein/oncogene has been established in breast, ovarian, salivary gland, and gastric carcinomas and has been implicated in other neoplasms. Recently, overexpression of c-erb B2 has been demonstrated in hepatocellular carcinoma using enzyme-linked immunosorbent assay. Patients with hepatocellular carcinoma have a poor prognosis, and overexpression of c-erb B2 may have prognostic and treatment implications. The authors evaluated the expression and amplification of c-erb B2 in hepatic neoplasms utilizing routine immunohistochemistry and fluorescence in situ hybridization. Formalin-fixed paraffin-embedded tissue sections from 27 hepatocellular carcinomas and 7 hepatocellular adenomas were immunostained with anti-c-erb B2 utilizing a modified avidin-biotin technique following heat induced antigen retrieval. Ten sections from hepatocellular carcinomas were subjected to fluorescence in situ hybridization assay. Positive and negative controls stained appropriately. Slides were evaluated independently by two pathologists. None of the hepatocellular carcinomas or hepatocellular adenomas was immunoreactive with anti-c-erb B2. Adjacent cirrhotic liver parenchyma, present in 11 cases, was also uniformly negative. None of hepatocellular carcinomas showed any evidence of c-erb B2 amplification by fluorescence in situ hybridization. Immunoreactivity for c-erb B2 was not demonstrated in hepatocellular adenomas, cirrhotic livers, or hepatocellular carcinomas using routine immunohistochemical methods. C-erb B2 amplification was not demonstrated in hepatocellular carcinomas. Neither overexpression nor amplification of c-erb B2 (Her2/ ) can be regarded as a useful prognostic factor in hepatocellular carcinoma.
人类c-erb B2原癌基因（Her2/）编码一种185-kD的酪氨酸激酶家族跨膜假定生长因子受体。这种癌蛋白/癌基因的过表达或扩增已在乳腺癌、卵巢癌、唾液腺癌和胃癌中得到证实，并与其他肿瘤有关。最近，使用酶联免疫吸附测定法已证实在肝细胞癌中存在c-erb B2过表达。肝细胞癌患者预后较差，c-erb B2过表达可能具有预后和治疗意义。作者利用常规免疫组织化学和荧光原位杂交技术评估了肝脏肿瘤中c-erb B2的表达和扩增情况。采用改良抗生物素蛋白-生物素技术，在热诱导抗原修复后，用抗c-erb B2对27例肝细胞癌和7例肝细胞腺瘤的福尔马林固定石蜡包埋组织切片进行免疫染色。对10例肝细胞癌切片进行荧光原位杂交检测。阳性和阴性对照染色适当。由两位病理学家独立评估切片。所有肝细胞癌或肝细胞腺瘤均未与抗c-erb B2发生免疫反应。11例患者存在的相邻肝硬化肝实质也均为阴性。荧光原位杂交未显示任何肝细胞癌有c-erb B2扩增的证据。使用常规免疫组织化学方法，在肝细胞腺瘤、肝硬化肝脏或肝细胞癌中均未显示c-erb B2的免疫反应性。肝细胞癌中未显示c-erb B2扩增。c-erb B2（Her2/）的过表达或扩增均不能被视为肝细胞癌的有用预后因素。
